2011
Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens. Clinical Infectious Diseases 2011;52(1):31–40
Ethan Rubinstein,1 Tahaniyat Lalani,2,3 G. Ralph Corey,2,3 Zeina A. Kanafani,11 Esteban C. Nannini,12 Marcelo G. Rocha,15 Galia Rahav,16 Michael S. Niederman,4,5 Marin H. Kollef,6 Andrew F. Shorr,7 Patrick C. Lee,8 Arnold L. Lentnek,9 Carlos M. Luna,13 Jean-Yves Fagon,17 Antoni Torres,18 Michael M. Kitt,a Fredric C. Genter,10 Steven L. Barriere,10 H. David Friedland,a Martin E. Stryjewski,2,14 for the ATTAIN Study Groupb
1 Section of Infectious Diseases Department of Internal Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada; 2 Department of Medicine, Duke Clinical Research Institute and 3 Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina; 4 Winthrop-University Hospital, Mineola, and 5 State University of New York at Stony Brook, Stony Brook, New York; 6 Pulmonary and Critical Care Division, Washington University School of Medicine, St. Louis, Missouri; 7 Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC; 8 Baystate Medical Center, Springfield, Massachusetts; 9 Wellstar Infectious Disease, Marietta, Georgia; 10 Theravance Inc., South San Francisco, California; 11 American University of Beirut Medical Center, Beirut, Lebanon; 12 Department of Infectious Diseases, School of Medicine, Universidad Nacional de Rosario, Rosario and 13 Department of Internal Medicine, Pulmonary Diseases Division, Hospital de Cli´nicas, Universidad de Buenos Aires, and 14 Department of Medicine and Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno, Buenos Aires, Argentina; 15Intensive Care Unit, Pavilha˜o Pereira Filho, Irmandade da Santa Casa, Porto Alegre, Brazil; 16 Division of Infectious Diseases Department of Medicine, Sheba Medical Center, Tel Hashomer, Israel; 17 Assistance Publique-Hoˆpitaux de Paris, Universite´ Paris-Descartes, Paris, France; 18 Division of Pulmonary Medicine, Clinic Institute of Thorax, Hospital Clinic of Barcelona-Institut d'Investigacions Biome`diques August Pi i Sunyer, University of Barcelona, Ciber de Enfermedades Respiratorias, Barcelona, Spain
Luna CM, Rodríguez-Noriega E, Bavestrello L, Gotuzzo E; Grupo Latinoamericano de Trabajo sobre Resistencia en Gram Positivos. Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in Latin America. Rev Chilena Infectol. 2010 Aug;27 Suppl 2:S94-103.
Luna CM, Rodríguez-Noriega E, Bavestrello L, Gotuzzo E. Treatment of methicillin-resistant Staphylococcus aureus in Latin America. Braz J Infect Dis. 2010 Dec;14 Suppl 2:S119-27.
Abstract
The global spread of MRSA means it is now a pathogen of worldwide public health concern. Within Latin America, MRSA is highly prevalent, with the proportion of S. aureus isolates that are methicillin-resistant on the rise, yet resources for managing the infection are limited. While several guidelines exist for the treatment of MRSA infections, many are written for the North American or European setting and need adaptation for use in Latin America. In this article, we aim to emphasize the importance of appropriate treatment of MRSA in the healthcare and community settings of Latin America. We present a summary of the available guidelines and antibiotics, and discuss particular considerations for clinicians treating MRSA in Latin America.
2010
Clinical and economic burden of pneumonia among adults in Latin America. Isturiz RE, Luna CM, Ramirez J. Int J Infect Dis. 2010 Oct;14(10):e852-6.
Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America. Rodríguez-Noriega E, Seas C, Guzmán-Blanco M, Mejía C, Alvarez C, Bavestrello L, Zurita J, Labarca J, Luna CM, Salles MJ, Gotuzzo E. Int J Infect Dis. 2010 Jul;14(7):e560-6.
Pandemic (H1N1) 2009 virus and Down syndrome patients. Pérez-Padilla R, Fernández R, García-Sancho C, Franco-Marina F, Aburto O, López-Gatell H, Bojórquez I. Emerg Infect Dis. 2010 Aug;16(8):1312-4.
La neumonía hospitalaria o neumonía nosocomial, así como la neumonía asociada a ventilación mecánica, se definen como los procesos neumónicos que aparecen después de las primeras 48 horas de pernoctancia hospitalaria y en el caso específico de la neumonía asociada a ventilación mecánica (NAVM), que no estaba incubada en el momento del ingreso (1) y se desarrolla 48 horas después de la intubación... [Leer artículo completo]